Breaking Finance News

Nektar Therapeutics (NDAQ:NKTR) target bumped up to $50.00, released a research note earlier today by Canaccord Genuity

Boasting a price of $37.37, Nektar Therapeutics (NDAQ:NKTR) traded 2.07% higher on the day. With the last stock price close up 18.06% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Nektar Therapeutics has recorded a 50-day average of $23.01 and a two hundred day average of $20.46. Volume of trade was down over the average, with 1,111,426 shares of NKTR changing hands under the typical 1,181,750

Canaccord Genuity raised the target price of Nektar Therapeutics (NDAQ:NKTR) to $50.00 indicating a possible upside of 0.34%.

Previously on 8/17/2017, Evercore ISI released a statement on Nektar Therapeutics (NDAQ:NKTR) upped the target price from $0.00 to $20.00 that suggested an upside of 0.08%.

See Chart Below

Nektar Therapeutics (NDAQ:NKTR)

Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $25.02 Nektar Therapeutics’s market capitalization is currently $0.

Brief Synopsis On Nektar Therapeutics (NDAQ:NKTR)

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.